Basit öğe kaydını göster

dc.contributor.authorBayraktar , Y
dc.contributor.authorUzunalimoğlu , B
dc.contributor.authorArslan , S
dc.contributor.authorKoseoğlu , T
dc.contributor.authorKayhan , B
dc.contributor.authorTelatar , H
dc.date.accessioned2019-12-10T11:12:05Z
dc.date.available2019-12-10T11:12:05Z
dc.date.issued1993
dc.identifier.issn0017-5749
dc.identifier.urihttps://doi.org/10.1136/gut.34.2_Suppl.S101
dc.identifier.urihttp://hdl.handle.net/11655/15009
dc.description.abstractThis paper presents the preliminary results of a study designed to evaluate the effects of alpha interferon in chronic hepatitis B. After six months' treatment with interferon alfa-2b (5 million units (MU), three times weekly) 15 of 25 (60%) patients achieved seroconversion of hepatitis B e antigen, 17 (68%) normalised alanine aminotransferase (ALT) activity, and 15 (60%) showed a decrease in the inflammatory reaction on liver histology. No seroconversions occurred in the control group (n=10), and none of the control patients achieved a normal ALT or showed a reduction in the inflammatory reaction. Adverse effects were experienced by most patients who received interferon but none warranted stopping the treatment.
dc.language.isoen
dc.publisherBritish Med Journal Publ Group
dc.relation.isversionof10.1136/gut.34.2_Suppl.S101
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGastroenterology & Hepatology
dc.titleEffects Of Recombinant Alpha-Interferon On Chronic Active Hepatitis-B - Preliminary-Results
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/conferenceObject
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalGut
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume34
dc.identifier.issue2
dc.identifier.startpageS101
dc.identifier.endpageS101
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster